Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer

International Journal of Cancer

Volumn 125, Issue 8, 2009, Pages 1912-1920

  Andrade Filho, Pedro A ^a,b   López Albaitero, Andrés ^a   Xi, Liqiang ^c   Gooding, William ^a   Godfrey, Tony ^c   Ferris, Robert L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Head and neck cancer; MAGE; QRT PCR; T cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HLA A ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 6; MESSENGER RNA; UNCLASSIFIED DRUG; GAMMA INTERFERON; MAGEA3 PROTEIN, HUMAN; MAGEA6 PROTEIN, HUMAN; PEPTIDE FRAGMENT; SMALL INTERFERING RNA; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIGESTIVE SYSTEM CANCER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; CASE CONTROL STUDY; COMPARATIVE STUDY; CYTOTOXICITY; DNA METHYLATION; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; LUNG NEOPLASMS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70349242372     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24590     Document Type: Article

References (40)

1. Vikram B, Strong EW, Shah JP, Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984;6:734-737 (Pubitemid 14185491)
2. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-369 (Pubitemid 24299325)
3. Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001;7:895s-901s. (Pubitemid 33600943)
4. Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini JC, Romero P. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 1997;57:735-741 (Pubitemid 27085659)
5. Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli GC, Ferrari C, et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol 2004;40:102-109 (Pubitemid 38064718)
6. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006;176:3402-3409 (Pubitemid 43363987)
7. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-3296 (Pubitemid 38263721)
8. Kienstra MA, Neel HB, Strome SE, Roche P. Identification of NYESO- 1. MAGE-1, and. MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003;25:457-463
9. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, Itoh K, Ishikawa T. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 1995;64:304-308
10. Lee KD, Eura M, Ogi K, Nakano K, Chikamatsu K, Masuyama K, Ishikawa T. Expression of the MAGE-1, -2, -3, -4, and -6 genes in non-squamous cell carcinoma lesions of the head and neck. Acta Otolaryngol 1996;116:633-639 (Pubitemid 26226392)
11. Park JW, Kwon TK, Kim IH, Sohn SS, Kim YS, Kim CI, Bae OS, Lee KS, Lee KD, Lee CS, Chang HK, Choe BK, et al. A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods 2002;266:79-86.
12. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007;29:163-188 (Pubitemid 46167784)
13. Sirianni N, Ha PK, Oelke M, Califano J, Gooding W, Westra W, Whiteside TL, Koch WM, Schneck JP, DeLeo A, Ferris RL. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:6929-6937 (Pubitemid 39383043)
14. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986;5:943-949
15. Parham PBC, Bodmer WF. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol 1979;123:342-349
16. Parham PBW. Monoclonal antibody to a human histocompatibility alloantigen. HLA-A2. Nature 1978;276:397-399
17. Goldman JM, Hibbin J, Kearney L, Orchard K, Th'ng KH. HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells. Br J Haematol 1982;52:411-420
18. Ferris RL, Xi L, Raja S, Luketich JL, Wang J, Gooding W, Kelly L, Ching J, Godfrey TE. Application of novel tumor markers for molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck (SCCHN). Cancer Res 2005;65:2147-2156
19. Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, Chen Z, Godfrey TE, Ferris RL. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004;64:1861-1866.
20. ABI Prism 7700 Sequence Detection System Technical Bulletin 2. Relative quantization of gene expression: Applied Biosciences, 1997.
21. Mailliard RB W-KA, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-5937 (Pubitemid 39129387)
22. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M. 5-aza-2′-deoxycytidine- induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002;8:2690-2695 (Pubitemid 34856358)
23. Wang X, Liang B, Rebmann V, Lu J, Celis E, Kageshita T, Grosse- Wilde H, Ferrone S. Specificity and functional characteristics of anti- HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens 2003;62:139-148 (Pubitemid 36981421)
24. Ferris RL, Xi L, Raja S, Hunt JL, Wang J, Gooding WE, Kelly L, Ching J, Luketich JD, Godfrey TE. Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck. Cancer Res 2005;65:2147-2156 (Pubitemid 40490121)
25. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz- Cabello F, Garrido F. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′- deoxycytidine treatment. Int J Cancer 2001;94:243-251 (Pubitemid 32911420)
26. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD341 progenitor- derived dendritic cells. J Exp Med 2004;199:1503-1511 (Pubitemid 38780405)
27. Lethe B, van der Bruggen P, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 1997;7(suppl 2):S83-8. (Pubitemid 27501630)
28. Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer 2000;86:818-826 (Pubitemid 30350197)
29. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002;20(suppl 4):A40-5. (Pubitemid 34087893)
30. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000;60:5228-5236 (Pubitemid 30739783)
31. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-11997 (Pubitemid 26013997)
32. Qiu G, Fang J, He Y. 5′ CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC. Clin Biochem 2006;39:259-266
33. Wischnewski F, Friese O, Pantel K, Schwarzenbach H. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1. MAGE-A2, MAGE-A3, and. MAGE-A12 gene promoters. Mol Cancer Res 2007;5:749-759
34. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-349 (Pubitemid 43837335)
35. Loriot A, Boon T, De Smet C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer 2003;105:371-376 (Pubitemid 36570050)
36. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 2008;14:1984-1996 (Pubitemid 351551107)
37. Kondo T, Zhu X, Asa SL, Ezzat S. The cancer/testis antigen melanoma- associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007;13:4713-4720 (Pubitemid 47294777)
38. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-1431 (Pubitemid 35414532)
39. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-11801 (Pubitemid 24985095)
40. Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 2002;132:2401S-5S.